Albumin, fatty-acid chains, and the engineering that made a weekly incretin possible
An accumulation model, drawn from published parameters, with its assumptions stated.
Dosing
Page 21 of 31 of this archive, newest first.
The supply gap as a clinical event
The trials studied planned withdrawal. Almost nobody stops that way.
South Africa pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Choosing a needle for a subcutaneous peptide
Gauge affects pain and flow rate rather than depth. A finer needle is more comfortable and slower, and with a viscous solution the difference is noticeable.
What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Dose-limiting: a definition worth being strict about
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The Netherlands pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
Why a drug that acts on the pancreas changes what food tastes like
A tour of the tissues where the receptor is expressed, and what happens in each.
Non-responders, and the honest state of the evidence about them
The mechanism is well described. The variance is not.
Why the fifth week of a dulaglutide dose feels different from the first
An accumulation model, drawn from published parameters, with its assumptions stated.
The convention nobody explains before handing over the vial
The graduation interval differs between barrel sizes, and a 1 mL barrel is frequently marked in two-unit steps. Reading one as though it were marked in single units halves…
What the new Norway guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Canada pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The shortage years, and what they taught about interruption
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What we would need to measure to explain the response distribution
A catalogue of open questions, with an assessment of how likely each is to be resolved.
South Korea pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Constipation is the one that responds best to boring measures
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.